【缺藥訊息】 公告日期：2024/12/3 缺藥品項：Aprovel 錠劑 150 mg 缺藥原因：因廠商停產缺藥 配套措施：剩餘量保留慢箋回院調劑，請改用院內其他同類 ARB 藥品替代。

---

【藥品性質提示】
根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議 CKD >stage3 之老年人長期使用。
高血壓 (ARB) Diabetic nephropathy; Hypertension

Irbesartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptor.

Absorption: Rapidly absorbed
Bioavailability: 60 to 80%
Vd: 53 to 93 L
Metabolism: Hepatic, via CYP2C9 pathway
Excretion: Fecal 80%; Renal 20%
Elimination Half Life: 11 to 15 hr

Concomitant aliskiren use in diabetic patients.
Hypersensitivity to irbesartan or to any component of the product.

D (FDA)

Infant risk cannot be ruled out.

Common:
Gastrointestinal: Diarrhea, Heartburn.
Neurologic: Headache.
Respiratory: Upper respiratory infection.
Other: Fatigue.
Serious:
Hematologic: Thrombocytopenia.
Hepatic: Cholestasis, Hepatitis.
Musculoskeletal: Rhabdomyolysis.
Renal: Renal failure.
Other: Angioedema, face, lips, throat.

Diabetic nephropathy: target maintenance dose, 300 mg orally once daily.
Hypertension: 150 mg orally once daily; may titrate to MAX 300 mg once daily.

volume- or salt-depleted patients: start with 75 mg orally once daily.
hemodialysis: start with 75 mg orally once daily.